YM 230888Selective mGlu1 antagonist CAS# 446257-23-4 |
- YM155
Catalog No.:BCC2251
CAS No.:781661-94-7
Quality Control & MSDS
Number of papers citing our products
Chemical structure
3D structure
Cas No. | 446257-23-4 | SDF | Download SDF |
PubChem ID | 11682007 | Appearance | Powder |
Formula | C19H28N4OS | M.Wt | 360.52 |
Type of Compound | N/A | Storage | Desiccate at -20°C |
Solubility | Soluble to 100 mM in DMSO and to 100 mM in ethanol | ||
Chemical Name | N-cycloheptyl-6-[[[(2R)-oxolan-2-yl]methylamino]methyl]thieno[2,3-d]pyrimidin-4-amine | ||
SMILES | C1CCCC(CC1)NC2=C3C=C(SC3=NC=N2)CNCC4CCCO4 | ||
Standard InChIKey | SASNRPJKZVJWQW-OAHLLOKOSA-N | ||
Standard InChI | InChI=1S/C19H28N4OS/c1-2-4-7-14(6-3-1)23-18-17-10-16(25-19(17)22-13-21-18)12-20-11-15-8-5-9-24-15/h10,13-15,20H,1-9,11-12H2,(H,21,22,23)/t15-/m1/s1 | ||
General tips | For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months. We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months. Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it. |
||
About Packaging | 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial. 2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial. 3. Try to avoid loss or contamination during the experiment. |
||
Shipping Condition | Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request. |
Description | Selective mGlu1 antagonist (Ki = 13 nM). Inhibits mGlu1-mediated inositol phosphate production in rat cerebellar granule cells (IC50 = 13 nM). Displays antinociceptive and analgesic effects in vitro; exhibits no significant sedative effect on locomotor activity. |
YM 230888 Dilution Calculator
YM 230888 Molarity Calculator
1 mg | 5 mg | 10 mg | 20 mg | 25 mg | |
1 mM | 2.7738 mL | 13.8689 mL | 27.7377 mL | 55.4754 mL | 69.3443 mL |
5 mM | 0.5548 mL | 2.7738 mL | 5.5475 mL | 11.0951 mL | 13.8689 mL |
10 mM | 0.2774 mL | 1.3869 mL | 2.7738 mL | 5.5475 mL | 6.9344 mL |
50 mM | 0.0555 mL | 0.2774 mL | 0.5548 mL | 1.1095 mL | 1.3869 mL |
100 mM | 0.0277 mL | 0.1387 mL | 0.2774 mL | 0.5548 mL | 0.6934 mL |
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations. |
Calcutta University
University of Minnesota
University of Maryland School of Medicine
University of Illinois at Chicago
The Ohio State University
University of Zurich
Harvard University
Colorado State University
Auburn University
Yale University
Worcester Polytechnic Institute
Washington State University
Stanford University
University of Leipzig
Universidade da Beira Interior
The Institute of Cancer Research
Heidelberg University
University of Amsterdam
University of Auckland
TsingHua University
The University of Michigan
Miami University
DRURY University
Jilin University
Fudan University
Wuhan University
Sun Yat-sen University
Universite de Paris
Deemed University
Auckland University
The University of Tokyo
Korea University
- 2,4,5-Trimethoxybenzaldehyde
Catalog No.:BCN5498
CAS No.:4460-86-0
- Azathioprine
Catalog No.:BCC4762
CAS No.:446-86-6
- Genistein
Catalog No.:BCN5499
CAS No.:446-72-0
- Homoeriodictyol
Catalog No.:BCN6804
CAS No.:446-71-9
- BMS CCR2 22
Catalog No.:BCC7572
CAS No.:445479-97-0
- SGS 518 oxalate
Catalog No.:BCC7750
CAS No.:445441-27-0
- BMS-345541(free base)
Catalog No.:BCC5374
CAS No.:445430-58-0
- ZM 449829
Catalog No.:BCC2444
CAS No.:4452-06-6
- 1,4:3,6-Dianhydro-α-D-glucopyranose
Catalog No.:BCC8420
CAS No.:4451-30-3
- EBPC
Catalog No.:BCC6677
CAS No.:4450-98-0
- TC-O 9311
Catalog No.:BCC7900
CAS No.:444932-31-4
- AM1241
Catalog No.:BCC2551
CAS No.:444912-48-5
- 4-(4-(5-(Aminomethyl)-2-oxooxazolidin-3-yl)phenyl)morpholin-3-one
Catalog No.:BCC8646
CAS No.:446292-10-0
- RepSox
Catalog No.:BCC1887
CAS No.:446859-33-2
- Angiotensin II human
Catalog No.:BCC4087
CAS No.:4474-91-3
- RLLFT-NH2
Catalog No.:BCC3954
CAS No.:447408-68-6
- Ruixianglangdusu B
Catalog No.:BCN6869
CAS No.:447454-49-1
- Sulforaphane
Catalog No.:BCN2349
CAS No.:4478-93-7
- Betulonic acid
Catalog No.:BCN5500
CAS No.:4481-62-3
- NS 1643
Catalog No.:BCC7552
CAS No.:448895-37-2
- WY 45233 succinate
Catalog No.:BCC6125
CAS No.:448904-47-0
- 3-(4-Methoxyphenyl)-1-(pyrrol-1-yl)propan-1-one
Catalog No.:BCN1440
CAS No.:448905-82-6
- ITE
Catalog No.:BCC3902
CAS No.:448906-42-1
- Quercetin 3-O-[2-O-(6-O-E-feruloyl)-beta-D-glucopyranosyl]-beta-D-galactopyranoside
Catalog No.:BCN1439
CAS No.:448948-20-7
Antinociceptive profile of a selective metabotropic glutamate receptor 1 antagonist YM-230888 in chronic pain rodent models.[Pubmed:17597604]
Eur J Pharmacol. 2007 Sep 24;571(1):8-16.
Metabotropic glutamate receptor 1 (mGlu(1) receptor) has been suggested to play an important role in pain transmission. In this study, the effects of a newly-synthesized mGlu(1) receptor antagonist, (R)-N-cycloheptyl-6-({[(tetrahydro-2-furyl)methyl]amino}methyl)thieno[2,3-d]pyrim idin-4-ylamine (YM-230888), were examined in a variety of rodent chronic pain models in order to characterize the potential analgesic profile of mGlu(1) receptor blockade. YM-230888 bound an allosteric site of mGlu(1) receptor with a K(i) value of 13+/-2.5 nM and inhibited mGlu(1)-mediated inositol phosphate production in rat cerebellar granule cells with an IC(50) value of 13+/-2.4 nM. It showed selectivity for mGlu(1) versus mGlu(2)-mGlu(7) subtypes and ionotropic glutamate receptors. YM-230888 recovered mechanical allodynia with an ED(50) value of 8.4 mg/kg p.o. in L5/L6 spinal nerve ligation models. It also showed antinociceptive response at doses of 10 and 30 mg/kg p.o. in streptozotocin-induced hyperalgesia models. In addition, it significantly reduced pain parameters at a dose of 30 mg/kg p.o. in complete Freund's adjuvant-induced arthritic pain models. Although YM-230888 showed no significant effect on rotarod performance time at doses of 10 or 30 mg/kg p.o., it significantly decreased it at a dose of 100 mg/kg p.o. On the other hand, YM-230888 showed no significant sedative effect in locomotor activity measurement up to 100 mg/kg p.o. These results suggest that the blockade of mGlu(1) receptors is an attractive target for analgesics. YM-230888 has potential as a new analgesic agent for the treatment of various chronic pain conditions. In addition, YM-230888 may be a useful tool for the investigation of mGlu(1) receptors.
Pharmacological effects of the metabotropic glutamate receptor 1 antagonist compared with those of the metabotropic glutamate receptor 5 antagonist and metabotropic glutamate receptor 2/3 agonist in rodents: detailed investigations with a selective allosteric metabotropic glutamate receptor 1 antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methy l-3,6-dihydropyridine-1(2H)-carboxamide].[Pubmed:18487514]
J Pharmacol Exp Ther. 2008 Aug;326(2):577-86.
The functional roles of metabotropic glutamate receptor (mGluR) 1 in integrative brain functions were investigated using a potent and selective mGluR1 allosteric antagonist, FTIDC [4-[1-(2-fluoropyridine-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N-methy l-3,6-dihydropyridine-1(2H)-carboxamide], in comparison with the mGluR5 allosteric antagonist and the mGluR2/3 orthosteric agonist in rodents. FTIDC reduced maternal separation-induced ultrasonic vocalization and stress-induced hyperthermia without affecting behaviors in the elevated plus maze. An mGluR5 antagonist, 2-methyl-6-(phenylethynyl)-pyridine (MPEP), and an mGluR2/3 agonist, LY379268 [(1R,4R,5S,6R)-4-amino-2-oxabicyclo[3.1.0]hexane-4,6-dicarboxylic acid], showed anxiolytic activities in these models, suggesting involvement of postsynaptic mGluR1 in stress-related responses comparable with mGluR5 and mGluR2/3. Analgesic effects of FTIDC were seen in the formalin test but not in the tail immersion test. FTIDC selectively blocked methamphetamine-induced hyperlocomotion and disruption of prepulse inhibition, whereas MPEP and LY379268 did not alter those behaviors, suggesting that pharmacological blockade of mGluR1 could result in antipsychotic-like effects. FTIDC did not elicit catalepsy or impair motor functions at 10 times higher dose than doses showing antipsychotic-like action. In conclusion, blockade of mGluR1 showed antipsychotic-like effects without impairing motor functions, whereas blockade of mGluR5 and activation of mGluR2/3 did not display such activities.